The 2025 BMW Charity Pro-Am presented by TD SYNNEX is June 2-8 at Thornblade Club and the Carolina Country Club. For tickets ...

BottleRock Napa, the prestigious music festival in the idyllic wine region, was a resounding success, featuring established ...

As Nanachi focuses on healing Riko after being attacked by a monster within the dangerous Abyss, Reg is sent to fetch ingredients to make some grub. Mash a whole Demonfish, entrails and all ...

Our guide goes over everything that we know so far about the upcoming Monster Mash event in Grow A Garden. The post Grow A ...

Shares of energy drink company Monster Beverage (NASDAQ:MNST) fell 5.2% in the pre-market session after the company reported disappointing first quarter 2025 results: while gross margin beat ...

At week 96, a reduction in fibrosis without worsening of MASH occurred in 7 of 61 patients (11%) in the placebo group, in 12 of 57 patients (21%) in the 28-mg efruxifermin group (difference from ...

Rezdiffra made headlines last year as the first drug cleared to treat MASH, with the FDA specifically clearing the drug in patients with stages F2 and F3 non-cirrhotic MASH. As the launch gains ...

Semaglutide shows promise in MASH treatment, achieving significant MASH resolution and fibrosis improvement in the ESSENCE trial. Tolerability issues and insurance coverage challenges lead to 20% ...

Known as a “silent disease”, metabolic dysfunction-associated steatohepatitis (MASH) is affecting a growing number of people, with an expected 27 million cases in the United States by 2030.

Monster Beverage Corporation MNST is expected to report first-quarter 2025 results on May 8, after the closing bell. The beverage company is anticipated to have witnessed revenue and earnings growth.